219817-42-2

Upstream product

• 27828-71-3 5-hydroxynicotinic acid 
• 100-39-0 benzyl bromide 
• 30766-22-4 methyl 5-hydroxy-3-pyridinecarboxylate 
• 100-51-6 benzyl alcohol 

Downstream Products

• 1400807-93-3 C₁₄H₁₄N₂O₂ 
• 1400807-94-4 C₁₄H₁₃N₅O 
• 1400807-96-6 5-(benzyloxy)pyridine-3-carbonitrile 
• 1400807-97-7 C₁₃H₁₁N₅O 
• 1400807-98-8 C₁₄H₁₃N₅O 
• 1008775-37-8 ethyl ({5-[({4-[3-(2-cyclohexylethoxy)benzoyl]piperazin-1-yl}carbonyl)amino]pyridin-3-yl}oxy)acetate 
• 1008764-22-4 4-[3-(2-cyclohexylethoxy)benzoyl]-N-[5-(2-hydroxyethoxy)pyridin-3-yl]piperazine-1-carboxamide 
• 1008775-36-7 N-{5-[2-(benzyloxy)ethoxy]pyridin-3-yl}-4-[3-(2-cyclohexylethoxy)benzoyl]piperazine-1-carboxamide 
• 1008775-35-6 N-[5-(benzyloxy)pyridin-3-yl]-4-[3-(2-cyclohexylethoxy)benzoyl]piperazine-1-carboxamide 
• 1008764-31-5 ({5-[({4-[3-(2-cyclohexylethoxy)benzoyl]piperazin-1-yl}carbonyl)amino]pyridin-3-yl}oxy)acetic acid 
• 1008764-20-2 4-[3-(2-cyclohexylethoxy)benzoyl]-N-(5-hydroxypyridin-3-yl)piperazine-1-carboxamide 
• 1008775-34-5 5-(benzyloxy)nicotinoylazide 
• 263270-34-4 5-(benzyloxy)nicotinic acid 
• 1008775-33-4 sodium 5-benzyloxynicotinate 

Relevant academic research and scientific papers

BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease ca

Biaryl-propionic acid derivatives and their use as pharmaceuticals

The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cath

BIARYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease ca

Biaryl-Propionic Acid Derivatives and their Use as Pharmaceuticals

The present invention relates to compounds of the formula I, wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cath

TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

TRICYCLIC GYRASE INHIBITORS

Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND

The present invention provides compounds which promote erythropoietin production. Compounds represented by the following general formula (1) or pharmacologically acceptable salts thereof are provided: [wherein, R1 represents a group —X-Q1, X-Q1-Y-Q2 or X-Q1-Y-Q2-Z-Q3, X represents a single bond, —CH2— or the like, Q1 represents a monocyclic or bicyclic heterocyclic group which may have substituent(s), Y represents a single bond, —CH2—, or the like, Q2 represents a monocyclic or bicyclic hydrocarbon ring group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), Z represents a single bond, —CR11R12— or the like, R11 and R12 each independently represents a hydrogen atom, a halogen atom or the like, Q3 represents a phenyl group which may have substituent(s), a C3-C7 cycloalkyl group which may have substituent(s), a C3-C7 cycloalkenyl group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), R2 represents a C1-C3 alkyl group or the like, and R3 represents a hydrogen atom or a methyl group].

(3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING

The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. (Formula)

UREA COMPOUND OR SALT THEREOF

[Object] To provide a compound which can be used for the treatment of a disease associated with fatty acid amide hydrolase (FAAH), particularly urinary frequency, urinary incontinence and/or overactive bladder. [Means for solution] It is confirmed that a urea compound chemical-structurally characterized by having a piperidine or piperazine ring or a salt thereof has an excellent FAAH-inhibitory activity, and thus the present invention is completed. The urea compound or its pharmaceutically acceptable salt of the present invention can increase the effective bladder capacity and ameliorate the state of urinary frequency, and is therefore useful as an agent for treating urinary frequency, urinary incontinence and/or overactive bladder.

Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia

The present invention relates to a method of treating schizophrenia which comprises administering a therapeutically effective amount of a compound of formula I wherein R1, R2, and R3 are as defined in the specification or to pharmaceutically active acid-addition salts thereof.